Sign inCreate account

Report workspace

Add to folder
NCT01669096COMPLETEDanonymous

Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (Tuberculosis) Vaccine GSK 692342 in Healthy Adults

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 2

Modality

AI-normalized

protein therapy

Target

AI-normalized

mRNA expression modulation related to tuberculosis immunity

Indication / condition

AI-normalized

Tuberculosis

Intervention

Source record

GSK Biologicals' investigational TB vaccine GSK 692342

Source & freshness

Source record

NCT ID

NCT01669096

Original source

ClinicalTrials.gov

Source last updated

Mar 22, 2019

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01669096

Title

Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (Tuberculosis) Vaccine GSK 692342 in Healthy Adults

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 2

Condition raw

Tuberculosis

Condition normalized

Tuberculosis

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

mRNA expression modulation related to tuberculosis immunity

Target normalized

mRNA expression modulation related to tuberculosis immunity

Interventions

GSK Biologicals' investigational TB vaccine GSK 692342

Public preview

Source record

GSK's candidate tuberculosis vaccine, GSK 692342, aims to enhance immune response through mRNA expression profiling. Given the global burden of tuberculosis, particularly in developing regions, successful development could position GSK favorably in the vaccine market. The competitive landscape includes established vaccines like BCG and emerging candidates from other biopharma companies. Diligence should focus on regulatory pathways, potential partnerships for distribution, and the evolving landscape of tuberculosis treatment and prevention strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (Tuberculosis) Vaccine GSK 692342 in Healthy Adults

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT01669096

Status

COMPLETED

Phase

Phase 2

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

GSK's candidate tuberculosis vaccine, GSK 692342, aims to enhance immune response through mRNA expression profiling. Given the global burden of tuberculosis, particularly in developing regions, successful development could position GSK favorably in the vaccine market. The competitive landscape includes established vaccines like BCG and emerging candidates from other biopharma companies. Diligence should focus on regulatory pathways, potential partnerships for distribution, and the evolving landscape of tuberculosis treatment and prevention strategies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 22, 2019
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01669096

Indication

Tuberculosis

Modality

protein therapy

Target

mRNA expression modulation related to tuberculosis immunity

Intervention

GSK Biologicals' investigational TB vaccine GSK 692342

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.